IMVT - Immunovant Reports Positive Initial Phase 1 SAD and 300 mg Subcutaneous MAD Results for IMVT-1402

2023-09-26 08:00:34 ET

(24/7 MARKET NEWS) – Immunovant, Inc. (NASDAQ:IMVT) reported, this morning, that subcutaneously administered doses of IMVT-1402 achieved peak Immunoglobulin G (IgG) reductions that are similar to those previously observed with batoclimab, in initial data from a Phase 1 clinical trial in healthy adults, with no decrease in serum albumin below baseline or increase in low-density lipoprotein cholesterol (LDL-C) above baseline was observed after 4 weeks of dosing in the 300 mg multiple-ascending dose (MAD) SC cohort.

Immunovant trading at $29.02, up $8.28 (+43.09%), on 726.6K premarket shares traded.

Its 52-week range is $4.495 to $25.1284. It gapped through its 52-week high.

24/7 MARKET NEWS, INC Disclaimer

24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the …

The post Immunovant Reports Positive Initial Phase 1 SAD and 300 mg Subcutaneous MAD Results for IMVT-1402 appeared first on 24/7 Market News .

For further details see: